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Purpose: The common tool for diagnosing prostate cancer is serum prostate-specific antigen (PSA) testing and digital rectal 
examination, but the disadvantage of the high sensitivity and low specificity of PSA testing in the diagnosis of prostate cancer 
is a problem in clinical practice. We studied the correlation and diagnostic performance of the PSA level with cancer diagnosis, 
aggressiveness of prostate cancer (Gleason score>7), and bone metastasis.
Methods: A total 1,116 patients who underwent transrectal ultrasound and prostate biopsy were retrospectively studied. The 
patients were divided into subgroups by baseline PSA level as follows: ≤4, 4.1–10, 10.1–20, 20.1–50, 50.1–100, and >100 ng/
mL. The area under the receiver operating characteristic curve (AuROC), sensitivity, specificity, positive predictive value, negative 
predictive value, positive likelihood ratio, and negative likelihood ratio of each PSA level were evaluated for correlation and diagnostic 
performance with positive biopsy, Gleason score for aggressiveness, and bone metastasis.
Results: A positive biopsy result was found in 395 patients (35.39%). The PSA level corresponded well with the diagnosis of prostate 
cancer and a positive bone scan but moderately well with Gleason score as shown by AuROC for diagnosis of prostate cancer (0.82), 
positive bone scan (0.88), and Gleason score>7 (0.78). The specificity of a PSA level of 4.1–10, 10.1–20, 21.1–50, 50.1–100, and >100 ng/
mL in the diagnosis prostate cancer was 9.3, 55.5, 87.5, 98.2, and 99.7, respectively. 
Conclusions: The data showed a strong correlation of PSA level with tumor diagnosis, tumor aggressiveness, and bone metastasis. 
The prevalence of prostate cancer in this cohort was 35.39%. The chance of diagnosis of prostate cancer was greater than that for 
benign prostatic hyperplasia when the PSA level was higher than 20 ng/mL.
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INTRODUCTION
The prevalence of prostate cancer is increasing in Asia [1-4]. 
Currently, the common tools for diagnosis of prostate cancer 
are the digital rectal examination (DRE) and a serum prostate-
specific antigen (PSA) test. The combination of both DRE and 
PSA testing leads to a greater detection of prostate cancer. If 
abnormal results are shown on both tests, a prostate biopsy 
is recommended for a definitive tissue diagnosis of prostate 
cancer. 
 The high sensitivity and low specificity of PSA testing in the 
diagnosis of prostate cancer is a problem in clinical practice 
[5-8]. Use of PSA testing alone has reduced specificity owing 
to the influence of prostate volume and other factors such 
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 The statistical analysis of diagnostic values included the 
AuROC, sensitivity, specificity, positive predictive value, 
negative predictive value, LHR+, and LHR– of each PSA level.
RESULTS
Data from a total of 1,116 patients were analyzed. The pa-
tients’ average age was 68.02 ± 8.23 years (range, 42–93 years). 
The average PSA level for biopsy was 102.45 ng/mL (range, 
1–5,000 ng/mL). A positive biopsy result was found in 395 
patients (35.39%). Plots between PSA level and percentage 
of correlation for diagnosis of prostate cancer, Gleason score, 
and bone metastasis showed that the higher the PSA level, 
the higher the positive results for all variables studied (Fig. 1). 
The PSA level corresponded very well with the diagnosis of 
prostate cancer and a positive bone scan but only moderately 
well with Gleason score. This result was consistent with the 
area under the ROC curve for all variables. As shown in Table 
1 and Figs. 2-4, the PSA level provided high overall accuracy 
for the diagnosis of prostate cancer (0.82) and a positive bone 
scan (0.88) and moderate accuracy for Gleason score > 7 
(0.78). The chance of diagnosis of prostate cancer was more 
than that of benign prostatic hyperplasia when the PSA level 
was higher than 20 ng/mL.
 The sensitivity and specificity in the diagnosis of prostate 
as infection and manipulation. Even with this disadvantage, 
however, PSA measurement is still used in clinical practice 
given that no new biomarkers are currently accepted for the 
diagnosis of prostate cancer. The general cutoff for the PSA 
level is 4.0 ng/mL. With the use of this cutoff, the cancer de-
tection rate ranges from 35% to 42.3% for 10- to 12-core biopsy 
[9,10]. A higher PSA level may relate to a greater likelihood of 
positive tissue diagnosis, a higher Gleason score, and a greater 
likelihood of bone metastasis. 
 We studied the correlation and diagnostic performance of 
the PSA level for cancer diagnosis, aggressiveness of prostate 
cancer (Gleason score > 7), and bone metastasis in real clini-
cal practice. 
MATERIALS AND METHODS
Data for 1,116 patients who underwent an initial transrectal 
ultrasound and prostate biopsy at the Faculty of Medicine, 
Chiang Mai University, were retrospectively studied. All 10- 
to 12-core biopsy procedures were performed as outpatient 
procedures with local anesthesia. The patients’ demographic 
data such as age, PSA level, details of the pathologic report 
such as a positive diagnosis of cancer, Gleason score, and the 
result of the bone scan were recorded. The patients were 
divided into subgroups by baseline PSA level as follows: less 
than or equal 4, 4.1–10, 10.1–20, 20.1–50, 50.1–100, and more 
than 100 ng/mL. The area under the receiver operating char-
acteristic curve (AuROC), sensitivity, specificity, positive pre-
dictive value, negative predictive value, positive likelihood ra-
tio (LHR+), and negative likelihood ratio (LHR–) of each PSA 
level were evaluated for the correlation and diagnostic perfor-
mance with positive biopsy result, Gleason score for aggres-
siveness, and bone metastasis. This protocol was reviewed 
and approved by the Ethics Committee (Institutional Review 
Board) of the Faculty of Medicine, Chiang Mai University.
Fig. 1. Correlation of the prostate-specific antigen level with 
cancer diagnosis, agressiveness, and bone metastasis.
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Fig. 2. Area under the receiver operating characteristic curve 
(AuROC) of serum prostate-specific antigen in the prediction of 
tissue diagnosis.
 0 0.25 0.50 0.75 1.00
1-Specificity
AuROC of positive cancer
Table 1. Overall accuracy of serum PSA in the prediction of tis-
sue diagnosis, aggressiveness, and bone metastasis by AuROC
Serum PSA AuROC (95% CI)
Positive cancer 0.821 (0.792–0.849)
Aggressiveness 0.780 (0.737–0.823)
Bone 0.883 (0.808–0.886)
PSA, prostate-specific antigen; AuROC, area under the receiver operat-
ing characteristic curve; CI, confidence interval.
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higher than 20 ng/mL (Table 2). 
 For tumor aggressiveness (tumor with Gleason score > 7); 
at a PSA cutoff of 4 ng/mL, the specificity of detection of pros-
tate cancer with a Gleason score higher than 7 was 1.99%. 
A higher positive predictive value was found at higher PSA 
levels. The LHR+ was less than 5 at all PSA levels (Table 3). For 
bone metastasis, the results showed that the higher the cutoff, 
the higher the sensitivity, positive predictive value, and LHR+ 
(Table 4).
cancer for a PSA level of 4.1–10 ng/mL were 98.0% and 9.3%, 
respectively, and those for a PSA level of 10.1–20 ng/mL were 
81.5% and 55.5%, respectively. Lower sensitivity was found at 
higher PSA levels, whereas the specificity was elevated when 
the PSA level was higher. The specificity of PSA levels of 4.1–
10, 10.1–20, 21.1–50, 50–100, and >100 ng/mL in the diagnosis 
of prostate cancer was 9.3, 55.5, 87.5, 98.2, and 99.7, respec-
tively. The positive predictive value of PSA in prostate cancer 
diagnosis at a PSA level of 4.1–10 and 10.1–20 ng/mL was 37.2 
and 50.1, respectively. For a cancer diagnosis, the LHR+ was 
more than 5.0 (theoretical suggested LHR+) for a  PSA level 
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Fig. 3. Area under the receiver operating characteristic curve 
(AuROC) of serum prostate-specific antigen in the prediction of 
aggressiveness (Gleason score>7). 
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Fig. 4. Area under the receiver operating characteristic curve 
(AuROC) of serum prostate-specific antigen in the prediction of 
bone metastasis.
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Table 2. Diagnostic values of each PSA cutoff for tumor diagnosis
PSA (ng/mL) 
  cutoff point
Sensitivity Specificity PPV NPV LHR+ LHR– AuROC
4 98.0 (97.2–98.8) 9.3 (7.6–11.0) 37.2 (34.3–40.0) 89.3 (87.5–91.1) 1.08 (1.05–1.11) 0.22 (0.10–0.45) 0.536 (0.524–0.549)
10 81.5 (79.2–83.8) 55.5 (52.6–58.4) 50.1 (47.1–53.1) 84.6 (82.4–86.7) 1.83 (1.67–2.01) 0.33 (0.26–0.41) 0.685 (0.658–0.711)
20 65.8 (63.0–68.6) 87.5 (85.6–89.5) 74.3 (71.7–76.8) 82.4 (80.1–84.6) 5.27 (4.29–6.48) 0.39 (0.34–0.45) 0.767 (0.740–0.793)
50 47.8 (44.9–50.8) 98.2 (97.4–99.0) 93.6 (92.1–95.0) 77.5 (75.0–79.9) 26.54 (15.3–45.9) 0.53 (0.48–0.58) 0.730 (0.705–0.755)
100 34.4 (31.6–37.2) 99.7 (99.4–100.0) 98.6 (97.8–99.2) 73.5 (70.9–76.1) 124.12 (30.89–498.66) 0.66 (0.61–0.71) 0.671 (0.647–0.694)
95% Confidence interval in parentheses.
PSA, prostate-specific antigen; PPV, positive predictive value; NPV, negative predictive value; LHR+, positive likelihood ratio; LHR–, negative likelihood 
ratio; AuROC, area under the receiver operating characteristic curve. 
Table 3. Diagnostic values of each PSA cutoff for aggressiveness (Gleason score>7)
PSA (ng/mL) 
  cutoff point
Sensitivity Specificity PPV NPV LHR+ LHR– AuROC
4 97.8 (96.5–99.0) 1.99 (0.8–3.2) 33.6 (29.6–37.7) 63.6 (59.5–67.7) 1.00 (0.97–1.02) 1.12 (0.33–3.79) 0.500 (0.486–0.511)
10 91.6 (89.3–94.0) 36.4 (32.3–40.5) 42.3 (38.1–46.5) 89.5 (86.9–92.1) 1.44 (1.32–1.58) 0.23 (0.14–0.38) 0.730 (0.608–0.672)
20 83.2 (80.1–86.4) 62.8 (58.7–66.9) 53.2 (49.0–57.5) 88.0 (85.3–90.8) 2.24 (1.92–2.60) 0.27 (0.19–0.37) 0.700 (0.693–0.767)
50 66.5 (62.5–70.5) 79.3 (75.8–82.7) 62.0 (57.8–66.1) 82.3 (79.0–85.6) 3.20 (2.55–4.03) 0.42 (0.34–0.52) 0.540 (0.688–0.769)
100 52.0 (47.7–56.2) 87.8 (85.0–90.6) 68.4 (64.4–72.3) 78.2 (74.7–81.7) 4.25 (3.11–5.82) 0.55 (0.47–0.64) 0.699 (0.658–0.739)
95% Confidence interval in parentheses.
PSA, prostate-specific antigen; PPV, positive predictive value; NPV, negative predictive value; LHR+, positive likelihood ratio; LHR–, negative likelihood 
ratio; AuROC, area under the receiver operating characteristic curve.
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DISCUSSION 
Nowadays, the accepted tools for the diagnosis of prostate 
cancer are the DRE and serum PSA. PSA testing has been 
used in clinical practice since 1986 and has led to changes in 
screening and the early diagnosis of prostate cancer, which 
is followed by earlier treatment [5-8]. The widespread use of 
PSA screening had led to an increase in overall survival. More 
early-stage prostate cancer is diagnosed. The number of pros-
tate cancer patients with metastatic stages and comorbidities 
has decreased more than 25% owing to greater detection of 
confined tumors early. The usefulness of PSA testing has been 
shown for early diagnosis, assessing the response of treat-
ment, and determining tumor progression [11-13]. 
 The strengths and weaknesses of PSA testing have also 
been reported. A limitation of PSA testing is the risk of overdi-
agnosis and resultant negative biopsies owing to poor specific-
ity. Several conditions can affect the PSA level; PSA is pros-
tate-specific but is not prostate-cancer-specific. Elevations of 
the PSA level can be caused by other conditions such as large 
benign prostatic hyperplasia, prostatitis, prostate manipula-
tions, and recent ejaculation within 24 hours [14]. In clinical 
practice, the general PSA cutoff is 4.0 ng/mL. A lower cutoff 
leads to increased sensitivity but reduced specificity, which 
increases the detection of clinically insignificant prostate 
cancer. For patients with PSA between 4.0 and 10.0 ng/mL, 
the mean positive predictive valve of the diagnosis of prostate 
cancer is 21% (range, 18%–25%) [9]. In a pooled meta-analy-
sis study, the positive predictive value of PSA > 4.0 ng/mL was 
only 25% [9].
 In patients with PSA < 4 ng/mL and a normal DRE or an 
abnormal DRE result, the incidence of prostate cancer ranges 
from 4% to 9% and from 10% to 20%, respectively. Many pros-
tate cancers are missed with this cutoff. With a PSA level > 4 
ng/mL, in patients with a normal DRE or an abnormal DRE 
result, the incidence of prostate cancer is from 12% to 32% 
and from 42% to 72%, respectively [15-20]. Among a total of 
10,523 patients, Schroder et al. [21-25] diagnosed more pros-
tate cancer (430 cancer cases) in patients with a normal DRE 
result and PSA between 3.0 and 4.0 ng/mL [26]. Morgan et 
al. [26] studied age-specific reference ranges for PSA in 411 
black men with a PSA cutoff of 4 ng/mL. They found that 40% 
of cancers would be missed in black men with the use of tra-
ditional cutoff values. In men aged > 50 years, the possibility 
of prostate cancer in patients with serum PSA of 2.5–4 ng/mL, 
> 4 ng/mL, and > 10 ng/mL was 27.0%, 20% to 30%, and 42% 
to 64%, respectively.
 In a report using the PSA level to identity non–organ-con-
fined disease, the percentage of tumors with extraprostatic 
extension increased when patients had a high PSA level. The 
incidence of extraprostatic extension was 50% and 80% at a 
PSA level of 4 to 10 ng/mL and > 20 ng/mL, respectively [27]. 
 Age-adjusted PSA, free PSA, and PSA isoforms are used to 
increase the specificity of the detection of clinically significant 
cancer. Oesterling et al. [14] recommended the concept of 
age-related reference ranges. They showed that such ranges 
improve cancer-specific detection in old men and increase 
cancer detection in younger men. The detection of prostate 
cancer increased 18% in younger men and decreased 22% 
in older men. The 8% increase in organ-confined prostate 
cancer diminished in men aged < 59 years. In men aged > 60 
years, 21% fewer biopsies were performed with the result of 
missing 4% of organ-confined tumors. 
 Free PSA is usually lower in prostate cancer than in benign 
prostatic hyperplasia. A ratio of free PSA to total PSA (%f PSA) 
greater than 25% lowers the chance of prostate cancer com-
pared with a %f PSA <10% [28]. PSA isoforms are also useful 
in clinical practice among men who have a PSA level of 4 to 10 
ng/mL. With a cutoff of ≤25%, the detection of cancer is 95%, 
and the rate of sparing of biopsies is 20%. This test is most use-
ful in men with persistently elevated PSA levels who a have 
negative biopsy result. The [-2]proPSA isoform in prostate 
Table 4. Diagnostic values of each PSA cutoff for bone metastasis
PSA (ng/mL) 
  cutoff point
Sensitivity Specificity PPV NPV LHR+ LHR– AuROC
4 99.5 (98.9–100.0) 3.4 (1.6–5.2) 48.8 (43.9–53.8) 87.5 (84.2–90.8) 1.03 (1.00–1.06) 0.15 (0.02–1.24) 0.514 (0.500–0.528)
10 94.7 (92.5–96.9) 30.7 (26.2–35.3) 55.9 (51.0–60.8) 86.3 (82.9–89.7) 1.37 (1.24–1.51) 0.17 (0.09–0.32) 0.627 (0.592–0.663)
20 89.0 (85.9–92.4) 55.6 (50.7–60.5) 65.0 (60.3–69.7) 84.4 (80.9–88.0) 2.00 (1.70–2.35) 0.20 (0.13–0.30) 0.722 (0.682–0.764)
50 76.8 (72.7–81.0) 79.0 (75.0–83.0) 77.2 (73.1–81.3) 78.6 (74.6–82.7) 3.66 (2.78–4.83) 0.29 (0.22–0.38) 0.779 (0.738–0.820)
100 61.6 (56.8–66.4) 90.7 (87.9–93.6) 86.0 (82.6–89.4) 71.8 (67.4–76.2) 6.6: 4 (4.27–10.34) 0.42 (0.35–0.51) 0.762 (0.722–0.802)
95% Confidence interval in parentheses.
PSA, prostate-specific antigen; PPV, positive predictive value; NPV, negative predictive value; LHR+, positive likelihood ratio; LHR-, negative likelihood 
ratio; AuROC, area under the receiver operating characteristic curve.
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cancer serum is 25% to 95% of the free PSA function, when as-
sociated 6% and 19% in biopsy-negative men. At a sensitivity 
of 95% in men with PSA between 4 and 10 ng/mL, the speci-
ficity of proPSA, total PSA, and free PSA alone is 37%, 15%, 
and 27%, respectively [29,30].
 Our study showed the prevalence of prostate cancer to be 
35.39% and the positive predictive value in the diagnosis of 
prostate cancer when the PSA level was higher than 4 ng/mL to 
be 37.2%, which is a little higher than in a pooled meta-analysis 
study (25%). The incidence of prostate cancer in patients with 
serum PSA<4 ng/mL, >4–10 ng/mL, >10–20 ng/mL, >20–50 
ng/mL, >50–100 ng/mL, and >100 ng/mL was 10.67%, 16.12%, 
21.43%, 47.97%, 82.81%, and 98.55%, respectively. The chance 
of detection of prostate cancer was about 50% when biopsy 
was performed at a PSA level of more than 20 ng/mL. There 
was a strong correlation of PSA level with tumor diagnosis, 
tumor aggressiveness (Gleason score >7), and positive bone 
metastasis, as demonstrated by the AuROC in Table 1 and Figs. 
1-4. The average PSA level for biopsy was extraordinarily high 
(102.45±411.27 ng/mL) in this study, which can be explained 
by the very high PSA level (5,000 ng/mL) in one patient with 
bone metastasis. When we excluded this patient, the average 
PSA level was the same as in previous reports. We followed the 
National Comprehensive Cancer Network guideline for the 
definition of high-grade prostate cancer, which is cancer with a 
Gleason score>7. We did not include patients with a Gleason 
score of 4+3 as high-grade cancer in this study even though 
such cancers may be aggressive. 
 Diagnostic performances of the different cutoffs of the PSA 
level (4, 10, 20, 50, and 100 ng/mL) were determined for all 
variables. For diagnosis of prostate cancer, the higher the PSA 
cutoff, the lower the sensitivity and negative predictive value. 
Meanwhile, higher sensitivity and a higher LHR+ were found 
with a higher PSA level. In this study (Table 2), the cutoff of 
20 ng/mL may be the most appropriate for prostate cancer 
diagnosis owing to acceptable sensitivity, specificity, and 
LHR+ (more than 5.0, theoretically suggested LHR+) and the 
highest AuROC (0.767). In real practice, the PSA cutoff for use 
as the screening tool should be 4 ng/mL. Use of this level may 
provide a definite cure by radical therapy.
 Although an elevated correlation was found for Gleason 
score and PSA level, it did not perform well with the cutoffs 
assigned in clinical practice. The trend in diagnostic indexes 
toward the Gleason score were similar to prostate cancer 
diagnosis. Even at the highest PSA cutoff (100 ng/mL), speci-
ficity, positive predictive value, and LHR+ were only 80.1%, 
68.4%, and 2.61, respectively (Table 3). At the cutoff point for 
bone metastasis, 50 ng/mL, the AuROC was highest (0.779) 
and LHR+ was moderate (3.66 times), meaning that in pa-
tients who had a PSA level higher than 50 ng/mL, the chance 
of a bone scan being positive will be 3.66 times that in all pa-
tients tested in this dataset. One patient with a PSA level less 
than 4 ng/mL, Gleason score of 8, and positive DRE result 
had bone metastasis (1 in 8 patients, or 12.5%). This finding 
can be explained according to the study of Wymenga, which 
showed that 15.7% of prostate cancer cases had bone metas-
tasis when the PSA level was less than 10 ng/mL [31]. Because 
bone metastasis is very important for staging and treatment 
of prostate cancer, we also recommend that a bone scan be 
performed in patients with a PSA level of more than 10 ng/mL 
or a Gleason score of more than 7 or in patients with a clinical 
stage higher than T2 (intermediate/high risk) as the standard 
guideline.
 The limitation of this study was that only serum PSA was 
used for the diagnosis of prostate cancer, aggressiveness of 
cancer, and bone metastasis. The combination of PSA testing 
with DRE of the prostate and ultrasound imaging should en-
hance the sensitivity, specificity, and AuROC for the diagnosis 
of prostate cancer.
 In conclusion, with the use of serum total PSA in clinical 
practice, the prevalence of prostate cancer in this cohort was 
35.39%. A strong correlation was found between the PSA level 
and tumor diagnosis, tumor aggressiveness, and bone metas-
tasis. In real-life practice with serum total PSA testing, a greater 
chance of a positive cancer result, high-grade cancer, and 
bone metastasis was found in patients with a higher PSA level. 
CONFLICT OF INTEREST
No potential conflict of interest relevant to this article was re-
ported.   
ACKNOWLEDGMENTS
We would like to thank Faculty of Medicine, Chiang Mai Uni-
versity for funding this study.
REFERENCES
1. Baade PD, Youlden DR, Cramb SM, Dunn J, Gardiner RA. 
Epidemiology of prostate cancer in the Asia-Pacific region. 
Prostate Int 2013;1:47-58.
2. Ito K. Prostate cancer in Asian men. Nat Rev Urol 2014;11: 
197-212.
3. Nomura AM, Kolonel LN. Prostate cancer: a current perspec-
tive. Epidemiol Rev 1991;13:200-27.
Lojanapiwat, et al. PSA, diagnosis, tumor aggressiveness, bone metastasis
138
PROSTATE INTERNATIONAL
http://dx.doi.org/10.12954/PI.14054
4. Williams S, Chiong E, Lojanapiwat B, Umbas R, Akaza H; Asian 
Oncology Summit 2013. Management of prostate cancer in 
Asia: resource-stratified guidelines from the Asian Oncology 
Summit 2013. Lancet Oncol 2013;14:e524-34.
5. Thompson IM, Ankerst DP. Prostate-specific antigen in the 
early detection of prostate cancer. CMAJ 2007;176:1853-8.
6. Roobol MJ, Kranse R, Bangma CH, van Leenders AG, Blijen-
berg BG, van Schaik RH, et al. Screening for prostate cancer: 
results of the Rotterdam section of the European randomized 
study of screening for prostate cancer. Eur Urol 2013;64:530-9.
7. Schroder FH, van der Maas P, Beemsterboer P, Kruger AB, Ho-
edemaeker R, Rietbergen J, et al. Evaluation of the digital rectal 
examination as a screening test for prostate cancer. Rotterdam 
section of the European Randomized Study of Screening for 
Prostate Cancer. J Natl Cancer Inst 1998; 90:1817-23.
8. Schroder FH, Carter HB, Wolters T, van den Bergh RC, Gosse-
laar C, Bangma CH, et al. Early detection of prostate cancer in 
2007. Part 1: PSA and PSA kinetics. Eur Urol 2008;53:468-77.
9. Mistry K, Cable G. Meta-analysis of prostate-specific antigen 
and digital rectal examination as screening tests for prostate 
carcinoma. J Am Board Fam Pract 2003;16:95-101.
10. Obort AS, Ajadi MB, Akinloye O. Prostate-specific antigen: 
any successor in sight? Rev Urol 2013;15:97-107.
11. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, 
Church TR, et al. Mortality results from a randomized pros-
tate-cancer screening trial. N Engl J Med 2009;360:1310-9. 
12. Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding 
P, et al. Mortality results from the Göteborg randomised pop-
ulation-based prostate-cancer screening trial. Lancet Oncol 
2010;11:725-32.
13. Zappa M, Puliti D, Hugosson J, Schroder FH, van Leeuwen PJ, 
Kranse R, et al. A Different Method of Evaluation of the ERSPC 
Trial Confirms That Prostate-specific Antigen Testing Has a 
Significant Impact on Prostate Cancer Mortality. Eur Urol 2014 
Jan 7 [Epub]. http://dx.doi.org/10.1016/j.eururo.2013.12.055. 
14. Oesterling JE, Rice DC, Glenski WJ, Bergstralh EJ. Effect of 
cystoscopy, prostate biopsy, and transurethral resection of 
prostate on serum prostate-specific antigen concentration. 
Urology 1993;42:276-82.
15. Ito K, Kubota Y, Yamamoto T, Suzuki K, Fukabori Y, Kurokawa 
K, et al. Long term follow-up of mass screening for prostate 
carcinoma in men with initial prostate specific antigen levels 
of 4.0 ng/mL or less. Cancer 2001;91:744-51.
16. Bozeman CB, Carver BS, Caldito G, Venable DD, Eastham JA. 
Prostate cancer in patients with an abnormal digital rectal 
examination and serum prostate-specific antigen less than 
4.0 ng/mL. Urology 2005;66:803-7.
17. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia 
MS, Parnes HL, et al. Prevalence of prostate cancer among 
men with a prostate-specific antigen level < or =4.0 ng per mil-
liliter. N Engl J Med 2004;350:2239-46.
18. Krumholtz JS, Carvalhal GF, Ramos CG, Smith DS, Thorson P, 
Yan Y, et al. Prostate-specific antigen cutoff of 2.6 ng/mL for 
prostate cancer screening is associated with favorable patho-
logic tumor features. Urology 2002;60:469-73.
19. Beemsterboer PM, de Koning HJ, Kranse R, Trienekens PH, 
van der Maas PJ, Schröder FH. Prostate specific antigen test-
ing and digital rectal examination before and during a ran-
domized trial of screening for prostate cancer: European ran-
domized study of screening for prostate cancer, Rotterdam. J 
Urol 2000;164:1216-20.
20. Yamamoto T, Ito K, Ohi M, Kubota Y, Suzuki K, Fukabori Y, et 
al. Diagnostic significance of digital rectal examination and 
transrectal ultrasonography in men with prostate-specific 
antigen levels of 4 NG/ML or less. Urology 2001;58:994-8.
21. Schroder FH. Screening for prostate cancer (PC): an update 
on recent findings of the European Randomized Study of 
Screening for Prostate Cancer (ERSPC). Urol Oncol 2008; 
26:533-41.
22. Schroder FH, Roobol MJ, Andriole GL,Flesher N. Defining 
increased future risk for prostate cancer: evidence from a 
population based screening cohort. J Urol 2009;181:69-74.
23. Schroder FH, Hugosson J, Carlsson S, Tammela T, Maattanen 
L, Auvinen A, et al. Screening for prostate cancer decreases 
the risk of developing metastatic disease: findings from the 
European Randomized Study of Screening for Prostate Can-
cer (ERSPC). Eur Urol 2012;62:745-52.
24. Schroder FH, Denis LJ, Roobol M, Nelen V, Auvinen A, Tam-
mela T, et al. The story of the European Randomized Study of 
Screening for Prostate Cancer. BJU Int 2003;92 Suppl 2:1-13.
25. Roobol MJ, Kranse R, de Koning HJ, Schroder FH. Prostate-
specific antigen velocity at low prostate-specific antigen 
levels as screening tool for prostate cancer: results of second 
screening round of ERSPC (ROTTERDAM). Urology 2004; 
63:309-13.
26. Morgan TO, Jacobsen SJ, McCarthy WF, Jacobson DJ, McLeod 
DG, Moul JW. Age-specific reference ranges for prostate-
specific antigen in black men. N Engl J Med 1996;335:304-10.
27. Partin AW, Pearson JD, Landis PK, Carter HB, Pound CR, 
Clemens JQ, et al. Evaluation of serum prostate-specific an-
tigen velocity after radical prostatectomy to distinguish local 
recurrence from distant metastases. Urology 1994;43:649-59.
28. Benson MC, Whang IS, Pantuck A, Ring K, Kaplan SA, Olsson 
CA, et al. Prostate specific antigen density: a means of distin-
guishing benign prostatic hypertrophy and prostate cancer. J 
Urol 1992;147(3 Pt 2):815-6.
Vol. 2 / No. 3 / September 2014
139
PROSTATE INTERNATIONAL
http://dx.doi.org/10.12954/PI.14054
29. Lazzeri M, Haese A, Abrate A, de la Taille A, Redorta JP, Mc-
Nicholas T, et al. Clinical performance of serum prostate-spe-
cific antigen isoform [-2]proPSA (p2PSA) and its derivatives, 
%p2PSA and the prostate health index (PHI), in men with a 
family history of prostate cancer: results from a multicentre 
European study, the PROMEtheuS project. BJU Int 2013;112: 
313-21.
30. Hori S, Blanchet JS, McLoughlin J. From prostate-specific an-
tigen (PSA) to precursor PSA (proPSA) isoforms: a review of 
the emerging role of proPSAs in the detection and manage-
ment of early prostate cancer. BJU Int 2013;112:717-28.
31. Wymenga LF, Boomsma JH, Groenier K, Piers DA, Mensink 
HJ. Routine bone scans in patients with prostate cancer re-
lated to serum prostate-specific antigen and alkaline phos-
phatase. BJU Int 2001;88:226-30.
